| First Author | Tsubota K | Year | 2001 |
| Journal | Invest Ophthalmol Vis Sci | Volume | 42 |
| Issue | 1 | Pages | 101-10 |
| PubMed ID | 11133854 | Mgi Jnum | J:66543 |
| Mgi Id | MGI:1928604 | Citation | Tsubota K, et al. (2001) Improvement of lacrimal function by topical application of CyA in murine models of Sjogren's syndrome. Invest Ophthalmol Vis Sci 42(1):101-10 |
| abstractText | PURPOSE. The object of this study was to evaluate improvement of lacrimal gland (LG) function after topical cyclosporin A (CyA). METHODS. Topical CyA (0.01% and 0.1%) was applied to two mouse models of Sjogren's syndrome, the NFS/sld after thymectomy and the nonobese diabetic (NOD) mouse, and the functional integrity of the lacrimal gland was evaluated by measuring basal and stimulated tear secretion and its histologic integrity by examining it for apoptosis and lymphocyte invasion. RESULTS. After treatment with CyA at 0.1% in the NFS/sld mice, tear function increased, and there was a decrease in lymphocyte infiltration of the LG and a decrease in apoptotic figures among the acinar cells. In the NOD mice, tear function also improved, but there was no associated decrease in lymphocyte infiltration. However, the expression of Fas ligand (FasL) in NOD mice by infiltrating lymphocytes was suppressed with 0. 1% CyA eye drops. CONCLUSIONS. CyA appears to improve tear secretion in mouse models of Sjogren's syndrome by preventing lymphocyte-induced apoptosis of acinar cells. In one model this was achieved by preventing lymphocyte infiltration and in the other by reducing expression of FasL expression on infiltrating lymphocytes. |
